

# Significance of nuclear factor - kappa beta activation on prostate needle biopsy samples in the evaluation of Gleason score 6 prostatic carcinoma indolence

Marko Zupancic<sup>1</sup>, Boris Pospihalj<sup>2</sup>, Snezana Cerovic<sup>3</sup>, Barbara Gazic<sup>4</sup>, Primoz Drev<sup>4</sup>, Marko Hocevar<sup>5</sup>, Andraz Perhavec<sup>5</sup>

<sup>1</sup> Department of Urology, General Hospital Slovenj Gradec, Slovenj Gradec, Slovenia

<sup>2</sup> Department of Pathology, General Hospital Slovenj Gradec, Slovenj Gradec, Slovenia

<sup>3</sup> Institute of Pathology and Forensic Medicine, Military Medical Academy Belgrade, Belgrade, Serbia

<sup>4</sup> Department of Pathology, Institute of Oncology Ljubljana, Ljubljana, Slovenia

<sup>5</sup> Department of Surgical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia

Radiol Oncol 2020; 54(2): 194-200.

Received 3 January 2020

Accepted 24 March 2020

Correspondence to: Marko Zupančič, M.D., M.Sc., Department of Urology, General Hospital Slovenj Gradec, Gosposvetska cesta 1, SI-2380 Slovenj Gradec, Slovenia. E-mail: marko.zupancic@sb-sg.si

Disclosure: No potential conflicts of interest were disclosed.

**Background.** The goal of our study was to find out whether the immunohistochemical expression of nuclear factor-kappa beta (NF-κB) p65 in biopsy samples with Gleason score 3 + 3 = 6 (GS 6) can be a negative predictive factor for Prostate cancer (PCa) indolence.

**Patients and methods.** Study was conducted on a retrospective cohort of 123 PCa patients with initial total PSA ≤ 10 ng/ml, number of needle biopsy specimens ≥ 8, GS 6 on biopsy and T1/T2 estimated clinical stage who underwent laparoscopic radical prostatectomy and whose archived formalin-fixed and paraffin-embedded (FFPE) prostate needle biopsy specimens were used for additional immunohistochemistry staining for detection of NF-κB p65. Both cytoplasmic and nuclear NF-κB p65 expression in biopsy cores with PCa were correlated with postoperative pathological stage, positive surgical margins, GS and biochemical progression of disease.

**Results.** After follow-up of 66 months, biochemical progression (PSA ≥ 0.2 ng/ml) occurred in 6 (5.1%) patients, 3 (50%) with GS 6 and 3 (50%) with GS 7 after radical prostatectomy. Both cytoplasmic and nuclear NF-κB p65 expressions were not significantly associated with pathological stage, positive surgical margin and postoperative GS. Patients with positive cytoplasmic NF-κB reaction had significantly more frequent biochemical progression than those with negative cytoplasmic NF-κB reaction with PSA 0.2 ng/ml as cutoff point ( $p = 0.015$ ) and a trend towards more biochemical progression with PSA ≥ 0.05 ng/ml as cutoff point ( $p = 0.068$ ).

**Conclusions.** Cytoplasmic expression of NF-κB is associated with more biochemical progression and might be an independent prognostic factor for recurrence-free survival (RFS), but further studies including larger patient cohorts are needed to confirm these initial results.

Key words: nuclear factor-kappa beta; prostatic cancer; Gleason 6; needle biopsy sample

## Introduction

Prostate cancer (PCa) is the most common cancer in men in developed European countries, particularly those with a high proportion of elderly population,

with incidence rate up to 189 per 100.000.<sup>1</sup> In last two decades the disease has emerged as the most frequent cancer amongst men following rapid increases in the detection of a substantial number of early-stage PCa, particularly due to the increased

number of PSA testing. Recognizing that the expected men's life is obviously increasing, PCa also means increasing financial burden for individual countries.<sup>2</sup> Majority of men newly diagnosed with PCa will be candidates for primary curative therapy, either with radical prostatectomy or radiation, but many PCa, however, are low-grade, even indolent and the number of newly diagnosed PCa far outnumbers the number of lethal cases. Indolent PCa may exist for a long period without causing any symptoms or death, so the prediction of low risk and indolent PCa is needed to avoid overtreatment by unnecessary invasive therapies, and select men for active surveillance (AS).<sup>3-5</sup>

The nuclear factor-kappa beta (NF- $\kappa$ B) family of transcription factors plays a crucial role in inflammation as well as in the development and progression of cancer. Extensive evidence indicates that the NF- $\kappa$ B pathway is implicated in controlling the expression of genes involved in cell survival, proliferation, angiogenesis, and invasion.<sup>6</sup> Many studies indicate that activation of NF- $\kappa$ B signaling in PCa cells correlates with PCa progression, including chemoresistance, advanced stage, biochemical progression, and metastatic spread.<sup>7-11</sup> NF- $\kappa$ B is critical for human health, and aberrant NF- $\kappa$ B activation contributes to development of various autoimmune, inflammatory and malignant disorders including rheumatoid arthritis, atherosclerosis, inflammatory bowel diseases, multiple sclerosis and malignant tumors.<sup>12</sup> Despite the growing evidence for a role of NF- $\kappa$ B in prostate tumorigenesis and resistance to therapy, the mechanisms underlying the activation of NF- $\kappa$ B in PCa remain only partially understood.

The main goal of our study was to find out whether the immunohistochemical expression of NF- $\kappa$ B p65 in biopsy samples with Gleason score 3 + 3 = 6 (GS 6) is inversely correlated with prostatic carcinoma indolence.

## Patients and methods

### Patients

Our study was based on a retrospective cohort of 178 consecutive PCa patients whose archived formalin-fixed and paraffin-embedded (FFPE) prostate needle biopsy specimens were used for additional immunohistochemistry staining. All consecutive patients underwent the extraperitoneal laparoscopic radical prostatectomy (ELRP) or "nerve-sparing" extraperitoneal laparoscopic radical prostatectomy (N-S ELRP) without lymph

node dissection between 2006 and 2012 as a first treatment of PCa. All patients were followed-up for at least five years after surgery at Department of Urology in General Hospital Slovenj Gradec. Hospital patient's files were used for clinical data.

The inclusion criteria were total PSA  $\leq 10$  ng/ml, number of biopsy specimen  $\geq 8$ , histopathological result of prostate cancer GS 6 on biopsy and T1/T2 estimated clinical stage, based on clinical examination only. The exclusion criterion was the presence of chronic diseases in which the activation of NF- $\kappa$ B is common. After the screening review of the clinical data and histopathological revision of prostate needle biopsy specimens, done by two unrelated pathologists with extensive experience in PCa, 15 patients were excluded from the study, as they did not meet the criterion of GS. During the additional microtome cutting of archived FFPE prostate needle biopsy specimens for immunohistochemistry due to the lack of the tissue, another 40 patients were excluded. The final analysis in this study was performed on 123 patients. Based on a PSA levels, two biochemical progression were defined, at PSA cutoff point  $\geq 0.05$  ng/ml and  $\geq 0.2$  ng/ml, 6 months or more after radical prostatectomy. Recurrence-free survival (RFS) was defined as the period between the surgery and biochemical progression (i.e. first increase of PSA above one or both PSA cutoff points). 5 patients were excluded due to the initiation of hormonal treatment immediately after surgery, so regarding the biochemical progression 118 patients were analyzed.

For control group archived FFPE prostate needle biopsy specimens from 60 patients with PCa GS 7, 30 with 3 + 4 and 30 with 4 + 3, were used.

Study was approved by the Slovene National Medical Ethics Committee No 109/14.

### Tissue preparation and immunohistochemical staining

IHC staining for detection of NF- $\kappa$ B p65 was performed on 2-4  $\mu$ m FFPE tissue sections, dried at 56°C for 2 hours, using fully automated IHC system Ventana Benchmark XT (manufacturer Ventana ROCHE inc.). Epitope was retrieved on board employing heat-mediated epitope retrieval using high pH Cell Conditioning Solution 1 (cat No 950-124, manufacturer Ventana ROCHE inc.) for 88 minutes at 100°C. Epitope was detected using commercially available mouse monoclonal antibody NF- $\kappa$ B p65 (clone F-6; cat No sc-8008; manufacturer Santa Cruz Biotechnology inc.) directed against amino acids 1-286 of NF- $\kappa$ B p65 of human origin. Primary

TABLE 1. Patient characteristics

General, N = 123			
Mean Age, year, (range)	63.6 (50–75)		
Mean init. PSA, ng/ml, (range)	5.32 (1.32–9.51)		
Mean Prostate V, ml, (range)	38.3 (14–97)		
Mean Biopsy cores, n, (range)	9.6 (8–10)		
Total Biopsy cores, n	1.180		
Clinical stage			
T1, n, (%)	113 (91.9)		
T2, n, (%)	10 (8.1)		
Biopsy GS 3+3=6, n, (%)	123 (100)		
Surgery			
ELRP, n, (%)	87 (70.7)		
N-S ELRP, n, (%)	36 (29.3)		
Pathological result after RP			
N = 123	N of total P      % of total P		
pT classification			
T2	96      78.0		
T3a	23      18.7		
T3b	4      3.3		
Surgical margins			
Positive	13      10.6		
Negative	110      89.4		
Gleason score			
3+3=6	79      64.2		
3+4=7	37      30.1		
4+3=7	7      5.7		
Biochemical progression after RP			
N = 118	N (%)	GS 6	GS 7
BP		N( %)	N( %)
PSA 0,05–0.19 ng/ml	14 (11.8)	8(57.1)	6(42.9)
PSA ≥ 0,2 ng/ml	6 (5.1)	3(50)	3(50)

BP = biochemical progression; ELRP = laparoscopic radical prostatectomy; GS = Gleason score; N-S ELRP = "nerve-sparing" extraperitoneal laparoscopic radical prostatectomy; PSA = Prostate-specific antigen; RP = radical prostatectomy; V = volume

antibody was diluted 1:200 using DAKO REAL™ antibody diluent (cat No S2022; manufacturer DAKO Agilent technologies inc.) and incubated on board for 60 minutes at 37°C. Primary antibody was visualized using 3-step multimer detection system OptiView DAB IHC Detection Kit (cat No

760-700; manufacturer Ventana ROCHE inc.) according to manufacturer's instructions.

The staining was analysed by pathologist with extensive experience in PCa who was not familiar with patient's clinical data. For nuclear staining, positive result was reported when at least 5% nuclei of cancer cells showed unequivocal brown coloration.<sup>13</sup> To consider reaction as positive, nuclear brown coloration should exceed the effect of cytoplasmic overlapping. The intensity of cytoplasmic staining was assessed as negative, weak, moderate and strong, and for statistical analysis grouped as negative (negative, weak) and positive (moderate, strong).<sup>14</sup>

## Statistical analyses

Clinical, laboratory and pathological characteristics were summarized using frequency and percentage for categorical variables, and mean and range for continuous variables. RFS was calculated from the time of primary tumour excision, and was censored at the last contact date if there were no events. Association of NF-κB expression status with pathological findings was tested using Chi-square test. Survival curves were calculated by Kaplan-Meier's method and tested for statistical significance using log-rank test. Multivariate Cox regression model was used to test whether NF-κB expression status is an independent predictor of RFS; other covariates included in the model are known prognostic factors in prostate cancer: final Gleason score, surgical margin status and pathologic stage. The differences were considered statistically significant if the p values were less than 0.05. Software package SPSS 22.0 for Windows was used.

## Results

Table 1 shows patients characteristics and biochemical progression in patients after radical prostatectomy. Postoperative pathological stage 3 was noticed in 27 (22%) and positive surgical margins were detected in 13 patients (10.6%). biochemical progression (PSA ≥ 0.05 ng/ml) occurred in 20 (16.9%) patients (11 with GS 6 after radical prostatectomy and 9 with GS 7). Among 118 patients, clinically significant postoperative PSA ≥ 0.2 ng/ml was detected in six patients (5.1%), with GS 6 in 3 and GS 7 in 3. Positive cytoplasmic NF-κB staining was detected in 173 (56.9%) and positive nuclear

**TABLE 2.** Association of nuclear factor-kappa beta (NF-κB) p65 expression status in cytoplasm with pathological findings

N = 123	N	NF-κB p65 expression		P
		negative	positive	
pT status				
pT2	96	48	48	
pT3	27	12	15	0.667*
Surg. m.				
Negative	110	53	7	
Positive	13	7	6	0.774**
GS				
3 + 3 = 6	79	39	40	
3 + 4 = 7	37	17	20	
4 + 3 = 7	7	5	2	0.465***

\* pT2 versus pT3, \*\*negative versus positive surgical margin, \*\*\*3 + 3 = 6 versus 3 + 4 = 7 versus 4 + 3 = 7

GS = Gleason score; Surg. M. = surgical margin

**TABLE 3.** Cytoplasmic nuclera factor-kappa beta (NF-κB) p65 expression status in biopsy group postoperative Gleason score (GS) 6 and control biopsy group postoperative GS 7

	N	NF-κB p65 expression		P
		negative	positive	
3 + 3 = 6	123	60	63	
3 + 4 = 7	30	3	27	<0.001*
4 + 3 = 7	30	0	30	<0.001**

\* 3 + 3 = 6 versus 3 + 4 = 7, \*\*3 + 3 = 6 versus 4 + 3 = 7

NF-κB staining in 57 (18.7%) of the 304 analyzed biopsy cores with GS 6.

### Cytoplasmic NF-κB staining

Cytoplasmic NF-κB p65 expression was not correlated with pathological stage, positive surgical margin and postoperative GS (Table 2). Cytoplasmic

**TABLE 4.** Multivariate analysis of cytoplasmic nuclear factor-kappa beta (NF-κB) p65 expression and other clinicopathologic variables associated with recurrence-free survival (RFS)


	Hazard ratio (95% CI)	P
Cytoplasmic NF-κB p65 expression (negative vs. positive)	2.367 (0.908–6.170)	0.078
Postoperative Gleason score (6 vs. 7)	1.105 (0.406–3.008)	0.845
Surgical margin (negative vs. positive)	4.845 (1.646–14.260)	0.004
Pathologic stage (T2 vs. T3)	1.041 (0.339–3.194)	0.944

NF-κB p65 expression was significantly more common in biochemical progression with PSA cut off point  $\geq 0.2$  ng/ml ( $P = 0.015$ ) and there was a trend towards biochemical progression with PSA cut off point  $\geq 0.05$  ng/ml ( $P = 0.068$ ) (Figure 1). Cytoplasmic NF-κB p65 expression was positive in 57/60 control group patients with GS 7 (Table 3).

In multivariate analysis only positive surgical margin was significantly associated with worse RFS with a PSA cut off point  $\geq 0.05$  ng/ml, while postoperative Gleason score 7 and pathologic stage of the disease were not significantly associated with RFS (Table 4). Positive cytoplasmic NF-κB p65 expression negatively affects RFS with borderline statistical significance ( $p = 0.078$ ). When PSA cut off point was set to  $\geq 0.2$  ng/ml, none of the prognostic factors was significantly associated with RFS in multivariate analysis.

### Nuclear NF-κB staining

Nuclear NF-κB p65 expression was not associated with pathological stage, positive surgical margins and postoperative GS (Table 5), neither with biochemical progression (Figure 2) and did not differ from control group patients with GS 7 (Table 6).

**FIGURE 1.** Recurrence-free survival (RFS) in patients with positive and negative nuclear factor-kappa beta (NF-κB) p65 expression status in cytoplasm (N = 118).

**TABLE 5.** Association of nuclear factor-kappa beta (NF- $\kappa$ B) p65 expression status in nucleus with pathological findings

N = 123	N	NF-κB p65 expression		P
		negative	positive	
pT status				
pT2	96	81	15	0.769*
pT3	27	22	5	
Surg. m.				
Negative	110	92	18	1**
Positive	13	11	2	
GS				
3 + 3 = 6	79	66	13	0.989***
3 + 4 = 7	37	31	6	
4 + 3 = 7	7	6	1	

\* pT2 versus pT3, \*\*negative versus positive surgical margin, \*\*\* 3 + 3 = 6 versus 3 + 4 = 7 versus 4 + 3 = 7

GS = Gleason score; Surg. M. = surgical margin

In multivariate analysis only positive surgical margin was significantly associated with worse RFS with a PSA cut off point  $\geq 0.05$  ng/ml, while positive nuclear NF- $\kappa$ B p65 expression, postoperative Gleason score 7 and pathologic stage of the disease were not significantly associated with RFS (Table 7). When PSA cut off point was set to  $\geq 0.2$  ng/ml, none of the prognostic factors was significantly associated with RFS in multivariate analysis. Figure 3 shows difference in positive cytoplasmic and nuclear staining in patient with GS 6 and GS 7.

## Discussion

Increase in incidence of PCa since 1990s mostly starts with PSA testing, either in the form of all types of screening or on the basis of a suspicious

**TABLE 6.** Nuclear factor-kappa beta (NF- $\kappa$ B) p65 expression status in biopsy group GS 6 and control biopsy group GS 7


	N	NF- $\kappa$ B p65 expression		P
		negative	positive	
3+3=6	123	103	20	0.596*
3+4=7	30	24	6	
4+3=7	30	17	13	0.003**

\* 3+3=6 versus 3+4=7, \*\*3+3=6 versus 4+3=7

**TABLE 7.** Multivariate analysis of nuclear factor-kappa beta (NF- $\kappa$ B) p65 expression and other clinicopathologic variables associated with recurrence-free survival (RFS; recurrence defined as PSA  $\geq 0.05$ )

	Hazard ratio (95% CI)	P
NF- $\kappa$ B p65 expression (negative vs. positive)	0.254 (0.034–1.915)	0.184
Postoperative Gleason score (6 vs. 7)	1.078 (0.400–2.907)	0.882
Surgical margin (negative vs. positive)	4.838 (1.674–13.983)	0.004
Pathologic stage (T2 vs. T3)	1.232 (0.409–3.705)	0.711

digital rectal examination. Nevertheless, the most important part of diagnostic procedure is accurate histopathologic diagnosis, particularly in low-risk PCa where AS could be an option.<sup>15</sup> Despite the fact that in our study biopsy samples were evaluated by two experienced uropathologists, we recorded the postoperative upgrade of GS 6 to GS 7 in 44 patients (3 + 4 in 37 and 4 + 3 in 7), so biopsy undergrading was present in 35.8%. This is in concordance with literature reports where GS from needle biopsies underestimates the GS of the radical prostatectomy specimen in 28% to 57%.<sup>16</sup> Postoperative pathological stage 3 was noticed in 27 (22%), positive surgical margins were detected in 13 (10.6%)


**FIGURE 2.** Recurrence-free survival (RFS) in patients with positive and negative nuclear factor-kappa beta (NF- $\kappa$ B) p65 expression status in nucleus (N = 118).



and clinically significant biochemical progression (PSA  $\geq 0.2$  ng/ml) in 6 (5.1%) patients.

Molecular biomarkers offer the possibility to further stratify patients with similar clinicopathological parameters. Domingo-Domenech *et al.*<sup>9</sup> and Ross *et al.*<sup>10</sup> reported that tumors with nuclear NF- $\kappa$ B expression and no additional risk factors (i.e. low GS and low preoperative PSA) had the lowest rate of biochemical recurrence in the nuclear NF- $\kappa$ B positive group. In addition to nuclear staining, we included also the NF- $\kappa$ B cytoplasmic staining and contrary to reported results found that only the cytoplasmic NF- $\kappa$ B variable was associated with worse RFS. This association was statistically significant when PSA cut-off point for recurrence was set to  $\geq 0.2$  ng/ml ( $p = 0.013$ ) and borderline significant when PSA cut-off point was set to  $\geq 0.05$  ( $p = 0.057$ ). In multivariate analysis positive cytoplasmic NF- $\kappa$ B p65 expression remained negatively associated with RFS (PSA cut-off point  $\geq 0.05$ ) with borderline statistical significance ( $p = 0.078$ ).

The p65 subunit of NF- $\kappa$ B was expressed in the cytoplasm of 173 (56.9%) biopsy cores with GS 6. Only 57 (18.7%) biopsy samples also showed a nuclear staining of NF- $\kappa$ B p65, suggesting a constitutive activation of NF- $\kappa$ B in these tissues. Our results showed a positive correlation between NF- $\kappa$ B cytoplasmic staining and biochemical progression. The main differences with other studies relate to tissue sample type and biochemical progression definition. Unlike Domingo-Domenech *et al.*<sup>9</sup> and Ross *et al.*<sup>10</sup> the studies that used tissue samples from radical prostatectomy, our analysis is preoperative and is based on diagnostic biopsies and their predictive significance. Also, we used more stringent parameters for the determination of biochemical progression, which in previous works was only determined as a value of 0.4 ng/ml in two consecutive measurements. In the present study, NF- $\kappa$ B expression and its subcellular localization were highly variable among different specimens. In another study, nuclear NF- $\kappa$ B was found in 40% of PCa.<sup>8-13</sup> As in the current study, nuclear NF- $\kappa$ B did not significantly correlate with GS. The functional relevance of this immunoreactivity on NF- $\kappa$ B activation is not known. This limitation is based on the fact that p65/NF- $\kappa$ B nuclear translocation is necessary but not sufficient for NF- $\kappa$ B induced transcriptional activity, since both recruitment of NF- $\kappa$ B to target genes and NF- $\kappa$ B-induced transcriptional events after recruitment are needed for this to occur. Furthermore, the minimum percentage of tumor cells with nuclear p65 staining required to potentially result in detectable NF- $\kappa$ B-



**FIGURE 3.** Immunohistochemistry of nuclear factor-kappa beta (NF- $\kappa$ B) p65. (A) Positive cytoplasmic staining (GS 6). (B) Positive nuclear staining. (C) Positive cytoplasmic staining (GS 7). (D) Positive nuclear staining.

induced transcriptional activity remains uncharacterized. An important limitation of our study is a significant reduction in the size of diagnostic biopsies during microscopic reevaluation and diagnosis of PCa with GS 6.<sup>13,14</sup>

In our group of 20 patients who developed the biochemical progression with PSA cutoff point  $\geq 0.05$  ng/ml cytoplasmic NF- $\kappa$ B staining was detected in 14 (70%) and nuclear NF- $\kappa$ B staining in only 1 (5%), while among those 6 patients who had the biochemical progression with PSA cutoff point  $\geq 0.2$  ng/ml cytoplasmic NF- $\kappa$ B staining was noticed in all 6 (100%) and nuclear NF- $\kappa$ B staining in 1 (16.7%). Among several available selection criteria for AS worldwide, at our institution the EAU AS guidelines were used.<sup>17</sup> According to them all patients in our cohort had initial PSA below 10 ng/ml, biopsy GS 6, estimated clinical stage T1c-T2 and 82 of them (66.7%) had  $\leq 2$  positive cores on biopsy. From clinical point of view the biochemical progression of PCa after radical prostatectomy is defined with PSA  $\geq 0.2$  ng/ml.<sup>18</sup> In our group of 6 patients with biochemical progression at PSA cut-off point  $\geq 0.2$  ng/ml, positive cytoplasmic NF- $\kappa$ B staining was present in all 6 and all AS criteria were met in 5 (83.3%) patients. There was no positive nuclear NF- $\kappa$ B staining in any of these 5 patients. As a control group we used 60 patients with biopsy GS 7 and positive cytoplasmic NF- $\kappa$ B staining was present in 57 (95%) of them. Since patients with bi-

opsy GS 7 are not candidates for AS according to EAU AS guidelines there is no need for additional prognostic factor (i.e. positive cytoplasmic NF- $\kappa$ B staining). However, in patients with biopsy GS 6, an additional prognostic factor is needed in order to stratify these patients to a group where only AS is enough. According to our results, positive cytoplasmic NF- $\kappa$ B staining could be a negative predictive factor for the GS 6 PCa indolence and these patients are candidates for primary curative therapy.

There are several limitations of our study. Most importantly, all patients underwent surgical treatment, so the significance of NF- $\kappa$ B activation on prostate needle biopsy samples for disease progression was found only indirectly, based on biochemical progression and is most probably underestimated. Another important limitation is a small number of patients and single institution results.

## Conclusions

Cytoplasmic expression of NF- $\kappa$ B is associated with worse RFS, while it is not significantly associated with standard prognostic factors and remains an independent prognostic factor for RFS in multivariate analysis with borderline statistical significance. However, further studies, including larger patient cohorts are needed to confirm these initial results.

## References

1. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. *Eur J Cancer* 2018; **103**: 356-87. doi: 10.1016/j.ejca.2018.07.005.
2. Luengo-Fernandez R, Leal J, Gray A, Sullivan R. Economic burden of cancer across the European Union: a population-based cost analysis. *Lancet Oncol* 2013; **14**: 1165-74. doi: 10.1016/S1470-2045(13)70442-X.
3. Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. *J Urol* 2004; **171**: 1393-401. doi: 10.1097/01.ju.0000107247.81471.06
4. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. *JAMA* 2005; **293**: 2095-101. doi: 10.1001/jama.293.17.2095
5. Bangma CH, Roobol MJ. Defining and predicting indolent and low risk prostate cancer. *Crit Rev Oncol Hematol* 2012; **83**: 235-41. doi: 10.1016/j.critrevonc.2011.10.003
6. Karin M, Lin A. NF- $\kappa$ B at the crossroads of life and death. *Nat. Immunol* 2002; **3**: 221-7. doi: 10.1038/ni0302-221
7. May MJ, Ghosh S. Rel/NF-kappa B and I kappa B proteins: an overview. *Semin Cancer Biol* 1997; **8**: 63-73. doi: 10.1006/scbi.1997.0057
8. Lessard L, Karakiewicz PI, Bellon-Gagnon P, Alam-Fahmy M, Ismail HA, Mes-Masson AM, et al. Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. *Clin Cancer Res* 2006; **12**: 5741-5. doi: 10.1158/1078-0432.CCR-06-0330
9. Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Saulea S, et al. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. *Br J Cancer* 2005; **93**: 1285-94. doi: 10.1038/sj.bjc.6602851
10. Ross JS, Kallakury BV, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, et al. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. *Clin Cancer Res* 2004; **10**: 2466-72. doi: 10.1158/1078-0432.ccr-0543-3
11. Setlur SR, Royce TE, Sboner A, Mosquera JM, Demicheli F, Hofer MD, et al. Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. *Cancer Res* 2007; **67**: 10296-303. doi: 10.1158/1078-0432.ccr-0543-3
12. Park MH, Hong JT. Roles of NF- $\kappa$ B in cancer and inflammatory diseases and their therapeutic approaches. *Cells* 2016; **5**: E15. doi: 10.3390/cells5020015.
13. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localization of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. *Br J Cancer* 2005; **93**: 1019-23. doi: 10.1038/sj.bjc.6602796
14. Gannon PO, Lessard L, Stevens LM, Forest V, Bégin LR, Minner S, et al. Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer. *Eur J Cancer* 2013; **49**: 2441-8. doi: 10.1016/j.ejca.2013.02.026
15. Ganz PA, Barry JM, Burke W, Col NF, Corso PS, Dodson E, et al. NIH State-of-the-Science Conference Statement: role of active surveillance in the management of men with localized prostate cancer. *NIH Consens State Sci Statements* 2011; **28**: 1-27. PMID: 23392076
16. Lucia MS, Bostwick DG, Somerville MC, Fowler IL, Rittmaster RS. Comparison of classic and international society of urological pathology 2005 modified Gleason grading using needle biopsies from the reduction by dutasteride of prostate cancer events (REDUCE) trial. *Arch Pathol Lab Med* 2013; **137**: 1740-6. doi: 10.5858/arpa.2012-0447-OA
17. Komisarenko M, Martin LJ, Finelli A. Active surveillance review: contemporary selection criteria, follow-up, compliance and outcomes. *Transl Androl Urol* 2018; **7**: 243-55. doi: 10.21037/tau.2018.03.02
18. McCormick BZ, Mahmoud AM, Williams SB, Davis JW. Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies. *Indian J Urol* 2019; **35**: 6-17. doi: 10.4103/iju.IJU\_355\_18